NCT02838680已完成不适用
Transfemoral Replacement of Aortic Valve With HLT MeriDIAN Valve Feasibility Trial CANADA
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- HLT Inc.
- 入组人数
- 15
- 试验地点
- 4
- 主要终点
- Primary Endpoint: Mortality at 30 days
研究概览
简要总结
To evaluate the safety and performance of the HLT System in patients with severe aortic stenosis who present at high risk for aortic valve replacement surgery.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 70 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •70 years of age or older
- •Echocardiographic or hemodynamic based evidence of calcific (senile) aortic stenosis with one of the following: aortic valve EOA <1.0 cm2 or 0.6 cm2/m2 , mean aortic valve gradient >40 mmHg or peak aortic valve velocity >4 m/sec
- •Symptomatology due to aortic stenosis resulting in one of the following:
- •NYHA Functional Classification of II or greater
- •Presence of angina
- •Presence of syncope
- •Aortic valve annular diameter ≥ 24 and ≤26 mm measured by MSCT based on area or perimeter
- •STS score of ≥8, or documented heart team agreement of high risk for surgical aortic valve replacement (SAVR) due to frailty or comorbidities.
- •Geographically available, willing to comply with follow up and able to provide written informed consent
排除标准
- •Congenital unicuspid or bicuspid aortic valve, or noncalcified aortic valve; or valve eccentricity (calcific or otherwise) that in the opinion of the investigator could compromise procedural success.
- •Patients at high risk for coronary obstruction in the opinion of the investigator (e.g. combination of a coronary height < 12 mm and coronary sinus diameter < 30 mm)
- •Patients with low flow/low gradient aortic stenosis
- •Patients with significant annular calcification (e.g. Agatston score > 4000)
- •Pre-existing prosthetic heart valve in any position, or prosthetic ring
- •Severe aortic, mitral or tricuspid valve regurgitation
- •Moderate to severe mitral stenosis
- •Myocardial infarction within the past 30 days*
- •Echocardiographic evidence of intracardiac mass, thrombus or vegetation
- •LVEF < 30%
- •Severe pulmonary hypertension with pulmonary systolic pressure greater than two-thirds of systemic pressure
- •Hemodynamic instability requiring inotropic drug therapy within the past 14 days
- •Untreated clinically significant coronary artery disease requiring revascularization
- •Presence of significant aortic disease such as atheroma, thrombus, or aneurysm which, in the opinion of the investigator, precludes safe implant delivery
- •Blood dyscrasias defined as: acute leukopenia, acute anemia, acute thrombocytopenia, history of bleeding diathesis or coagulopathy
- •Patient ineligible for or refuses blood transfusions
- •Unfavorable peripheral vascular anatomy or disease (e.g. severe obstructive calcification, severe tortuosity or vessels < 6 mm) that would preclude passage of catheters from the femoral arterial access to the aorta as evidenced by peripheral MSCT
- •Active peptic ulcer or gastrointestinal bleeding within the past 90 days*
- •Symptoms of carotid or vertebral artery disease (e.g. stroke or transient ischemic attack) within past 6 month, or treatment of carotid stenosis within past two months*
- •Renal insufficiency as demonstrated by a serum creatinine > 2.5 mg/dL or end stage renal disease requiring chronic dialysis
- •Active infection requiring ongoing treatment
- •Need for emergent surgery or intervention other than the investigational procedure
- •Any therapeutic invasive cardiac procedure performed or planned to perform within 30 days of the index procedure except for PCI which is within 7 days of the index procedure*
- •Hypersensitivity or contraindication to procedural medication and device materials (e.g. titanium, nickel, pork) which cannot be adequately pre-medicated
- •Life expectancy < 1 year due to non-cardiac co-morbid conditions
- •Currently participating in any investigational drug or device studies that may confound the results of this study
- •History of any cognitive or mental health status that would interfere with study participation * At the time of procedure, if a subject's medical status has changed since enrollment, the subject shall be re-evaluated for eligibility.
结局指标
主要结局
Primary Endpoint: Mortality at 30 days
时间窗: 30 days
The primary safety endpoint is all-cause mortality at 30 days
次要结局
- Secondary Performance Endpoint 1: Procedural Device Performance(1 day)
- Secondary Performance Endpoint 2: Post-procedural Valve Performance (Severity of Aortic Valve Regurgitation)(1 week, 1, 6, 12, 24, 36, 48 and 60 months)
- Secondary Performance Endpoint 2: Post-procedural Valve Performance (Aortic Valve Gradient)(1 week, 1, 6, 12, 24, 36, 48 and 60 months)
- Secondary Safety Endpoint 3: Adverse Events(throughout the 5 year follow up period)
- Secondary Performance Endpoint 2: Post-procedural Valve Performance (Aortic Valve Effective Orifice Area)(1 week, 1, 6, 12, 24, 36, 48 and 60 months)
研究者
研究点 (4)
Loading locations...
相似试验
终止
不适用
Transfemoral Replacement of Aortic Valve With HLT MeriDIAN Valve Early Feasibility TrialAortic Valve StenosisNCT02799823HLT Inc.11
终止
不适用
HLT Meridian Valve CE Mark TrialAortic Valve StenosisNCT03805711HLT Inc.1
撤回
不适用
HLT transfemOral Replacement of aortIc Valve Via transcatherteriZatiON CANADASevere Aortic StenosisNCT02159794HLT Inc.
已完成
不适用
HLT transfemOral Replacement of aortIc Valve Via transcatherteriZatiONSevere Aortic StenosisAortic Valve StenosisNCT02157142HLT Inc.4
撤回
不适用
HLT® Meridian® TAVR Valve System Early Feasibility Study for Aortic RegurgitationAortic RegurgitationNCT05409378HLT Inc.